Mitral valve replacement with mechanical valves in children under two years of age  by Daou, L. et al.
994 Brief communications The Journal of Thoracic and
Cardiovascular Surgery
May 2001
years), after the first MVR (Table II). Indication for MVR was
mitral stenosis with symptoms. There was no operative mor-
tality or morbidity in these 3 patients.
Discussion. Our study demonstrates that in young chil-
dren with severe mitral lesions not amenable to repair,
MVR with mechanical valves is a reasonable alternative. In
early series, mortality was high, and an atrioventricular
canal was considered to increase the risk of early death. In
our series the postoperative mortality rate (<30 days) of
MVR in children younger than 2 years of age was 14% (n =
2; ie, close to the figures of MVR in older children).2,3
However, comparison between noncontemporary series is
not possible because intraoperative management and post-
operative care improved dramatically. The new models of
bileaflet mechanical valves, featuring a titanium ring,
enable the surgeon to rotate the prosthesis after implanta-
tion. Implantation of the valve in the supra-annular position
may enable us to choose a larger prosthesis and also to
avoid creation of subaortic obstruction.5 Resection of all the
submitral apparatus, which is usual in MVR in children and
infants, has not impaired the left ventricular function.
Transprosthetic mean gradient was acceptable despite the
size or the position of the mitral prosthesis. This transpros-
thetic gradient was measured by using Doppler ultrasonog-
raphy and could probably be overestimated.
Because of an infant’s growth, the prosthesis can become
restrictive, and repeated MVR is then required. The sizes of
prostheses implanted during this reoperation (25, 21, and
23) were not far from adult sizes. Therefore, we anticipate
that the total number of reoperations for MVR that an infant
operated on at a very young age will undergo is a priori no
more than that of an older child undergoing primary
implantation.
Oral anticoagulant therapy is feasible in infants. Rough
guidelines have been proposed to adapt the treatment to age
and weight ranges. Factors that may have an effect, such as
the infant’s weight, drug interactions, and diet, must be
taken into consideration. It is our policy to give antivitamin
K to all children receiving a prosthetic valve. There are,
however, centers that prefer using aspirin and dipyridamole.
Although we did not use this alternative therapy, the risk of
anticoagulation appeared acceptable in our study. Indeed,
only 1 patient (patient 2) had thrombosis of the mitral pros-
thesis 3 months after implantation. There was no mortality
or reoperation related to valve thrombosis, as has been
reported in other series.2-4
In conclusion, this study demonstrates that MVR with
mechanical valves in young infants is a reasonable alterna-
tive when mitral valve repair cannot be carried out or has
Repair of severe congenital mitral valve disease during the
first years of life is still a therapeutic challenge.1 Mechanical
valves are the most viable alternative when reconstructive
procedures have failed because in this age range early calcifi-
cations and very fast deterioration are likely to occur with bio-
prostheses.1-3 Most authors are reluctant to perform mitral
valve replacement (MVR) in young infants because of higher
morbidity and risk of anticoagulation.4 Here we report on 14
children who underwent MVR with mechanical prostheses
before 2 years of age.
Patients and methods. Between December 1985 and
December 1999, 14 children (median age, 5.6 months; medi-
an weight, 5.9 kg) underwent MVR with mechanical prosthe-
ses for untractable congestive heart failure, elevated pul-
monary artery pressure, or both. Mitral lesions and associated
cardiac malformations are shown in Table I. Eleven (78%)
patients had previous procedures before MVR (Table I), with
an attempted mitral valve repair in 6 (43%) patients. The
mitral valve was exposed through the right atrium and the
interatrial septum in 9 patients and through the left atrium in
the remaining 5 patients. Resection of the subvalvular mitral
apparatus was performed in all patients. Table II summarizes
the MVR characteristics.
Results. In-hospital mortality was 3 of 14, with 2 early
deaths (preoperative brain damage and periprosthetic mitral
regurgitation with death at redo operation) and 1 late death
after 7 months in the intensive care unit. One patient (patient
8) required implantation of a pacemaker for postoperative
atrioventricular block. One patient (patient 10) had transient
left ventricular dysfunction.
No hemorrhage was observed. One patient experienced
valve thrombosis 3 months after discharge and fully recovered
after thrombolytic therapy. At last follow-up examination
(mean follow-up was 5.7 ± 4 years; range, 4 months to 13
years), all patients were doing well (New York Heart
Association class II, 1 patient; New York Heart Association
class I, 10 patients), mean pulmonary pressure was less than 25
mm Hg, and left ventricular function was normal without any
treatment but oral anticoagulation. Three patients required
repeated MVR 5, 6, and 11 years, respectively (mean, 7.3 ± 2.4
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failed. In these rare but always complex situations for deci-
sion making, mortality was not high, and morbidity was
low. Long-term anticoagulation with antivitamin K was
feasible in infants with a low rate of severe complications.
Finally, hemodynamic status and prosthesis function were
excellent in all survivors at last follow-up.
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Table I. Demographic data at time of MVR, associated lesions, and previous procedures
Patient . Age Weight Type of mitral 
No (mo) (kg) valve dysfunction Associated lesions Previous procedures (age)
1 2 4 MR Incomplete AVC —
2 2 4.6 MR Aortic and subaortic stenosis Aortic valve dilation (3 d)
3 5 5.1 MR Complete AVC AVC repair, MV repair (4 mo)
4 5 5.1 MR — MV repair (3 mo)
5 5.5 5 MR Aortic stenosis Aortic valve dilatation (1 mo)
6 7 6.7 MS — —
7 8 5.8 MR Aortic stenosis Aortic valve dilatation (3 d)
8 9 5.5 MR VSD, subaortic stenosis VSD closure, subaortic stenosis resection,
MV repair, creation of ASD (5 mo)
9 14 8 MS Coarctation, bicuspid aortic 
valve, subaortic stenosis,
supra-MS, PDA Ligation of PDA (13 mo)
10 15 8.7 MS Aortic anulus hypoplasia,
supra-MS, coarctation CoA repair (9 mo), resection of supra-MS 
and MV repair (11 mo)
11 16 10.7 MR Incomplete AVC AVC repair, MV repair (6 mo)
12 18 8.5 MR Subaortic stenosis Resection of subaortic mitral tissue (2 mo)
13 19 8.6 MS Mild aortic stenosis —
14 22 8.3 MR Aortic stenosis Surgical aortic valvotomy, MV repair (1 mo)
MR, Mitral regurgitation; AVC, atrioventricular canal; VSD, ventricular septal defect; MS, mitral stenosis; MV, mitral valve; ASD, atrial septal defect; PDA, patent
ductus arteriosus; CoA, coarctation of the aorta.
Table II. MVR procedure and follow-up
Mean 
pressure 
gradient 
(mm Hg; 
mean,
Prosthesis Size Position Postoperative Delay Prosthesis Size Follow-up 7.7 ± 2.4 
Patient type (mm) (A/SA) Concomitant procedures death (y) type (mm) (mo) mm Hg)
1 CM 16 A/SA Ostium primum closure and incision 
of the coronary sinus tectum 9 d
2 CM 16 SA Ross-Manouguian procedure 4 4
3 CM 16 A — 5 SJM 25 86 6
4 CM 16 A — 20 10
5 CM 18 A — 6 SJM 21 98 7
6 SJM 19 A — 155 12
7 SJM 19 A — 102 8
8 CM 16 SA — 20 4
9 CM 16 SA Subaortic stenosis resection, coarctation 
repair, creation of ASD 7 10
10 CM 16 SA Widening of left atrium, creation of ASD 86 11
11 SJM 21 A — 47 4
12 SJM 21 A — 11 CM 23 140 9
13 CM 16 SA Creation of ASD 7 mo
14 SJM 23 A — 5 d
A, Annular position; SA, supra-annular position; CM, CarboMedics; SJM, St Jude Medical; ASD, atrial septal defect.
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